Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Ustekinumab Therapy for Severe Interstitial Granulomatous Dermatitis With Arthritis
Ustekinumab治疗中重度斑块状银屑病的疗效和安全性
Ustekinumab in Treatment of Refractory Paediatric Crohn Disease Response
Ustekinumab for Resistant Pediatric Crohn Disease
Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application
Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus
Ustekinumab for the treatment of Crohn's disease: can it find its niche?
Ustekinumab in Treatment of Refractory Paediatric Crohn Disease
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Ustekinumab treatment in patients with psoriasis undergoing hemodialysis
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial
Ustekinumab for Patients With Primary Biliary Cholangitis Who Have an Inadequate Response to Ursodeoxycholic Acid: A Proof-of-Concept Study
Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
Ustekinumab as a Therapeutic Option for Children With Refractory Enthesitis-Related Arthritis
Ustekinumab as therapy for psoriasis in a 2-year-old girl
Ustekinumab: a novel therapeutic option in Crohn's disease
Ustekinumab in Pediatric Crohn Disease Patients
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
Ustekinumab: when everything else fails?
Ustekinumab A Review of its Use in the Management of Moderate To Severe Plaque Psoriasis
Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity
Ustekinumab Biotherapy and Real-Time Psoriasis Capacitance Mapping: A Pilot Study
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
Ustekinumab treatment in a patient with psoriasis and systemic lupus erythematosus
Ustekinumab for chronic plaque psoriasis
Ustekinumab
Ustekinumab A New Option in Psoriasis Therapy